$22.03
1.19% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Arcturus Therapeutics Ltd Stock price

$22.03
+1.41 6.84% 1M
-10.83 32.96% 6M
-9.50 30.13% YTD
-5.17 19.01% 1Y
-28.10 56.05% 3Y
+11.61 111.42% 5Y
-89.34 80.22% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.26 1.19%
ISIN
IL0011280240
Symbol
ARCT
Sector
Industry

Key metrics

Market capitalization $588.71m
Enterprise Value $304.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.03
P/S ratio (TTM) P/S ratio 3.92
P/B ratio (TTM) P/B ratio 2.28
Revenue growth (TTM) Revenue growth -42.89%
Revenue (TTM) Revenue $150.16m
EBIT (operating result TTM) EBIT $-25.08m
Free Cash Flow (TTM) Free Cash Flow $-69.90m
Cash position $315.33m
EPS (TTM) EPS $-2.57
P/E forward negative
P/S forward 3.28
EV/Sales forward 1.70
Short interest 30.32%
Show more

Is Arcturus Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Arcturus Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Arcturus Therapeutics Ltd forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Arcturus Therapeutics Ltd forecast:

Buy
100%

Financial data from Arcturus Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
150 150
43% 43%
100%
- Direct Costs 3.42 3.42
-
2%
147 147
-
98%
- Selling and Administrative Expenses 46 46
1% 1%
31%
- Research and Development Expense 122 122
1% 1%
81%
-22 -22
124% 124%
-14%
- Depreciation and Amortization 3.42 3.42
53% 53%
2%
EBIT (Operating Income) EBIT -25 -25
128% 128%
-17%
Net Profit -69 -69
186% 186%
-46%

In millions USD.

Don't miss a Thing! We will send you all news about Arcturus Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcturus Therapeutics Ltd Stock News

Neutral
PRNewsWire
15 days ago
Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®, the world's first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, was approved for adults 18 years of age and older in November 2023 The updated sa-mRNA COVID-19 vaccine is tailored to protect against th...
Neutral
Business Wire
15 days ago
KING OF PRUSSIA, PA & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) granted approval and authorization for their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The updated vaccine is targeted to pr...
Positive
Seeking Alpha
about 2 months ago
Arcturus is close to launching the Kostaive COVID-19 vaccine in Japan, with ongoing work on variant protection and influenza vaccine. The company has been able to consistently derive research revenues, maintaining liquidity and avoiding debt, with potential for significant revenue from vaccine orders. Valuation suggests Arcturus may be undervalued compared to peers, with a revised model showing...
More Arcturus Therapeutics Ltd News

Company Profile

Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Head office Israel
CEO Joseph Payne
Employees 180
Founded 2013
Website www.arcturusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today